0001104659-19-061831.txt : 20191108
0001104659-19-061831.hdr.sgml : 20191108
20191108211610
ACCESSION NUMBER: 0001104659-19-061831
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191106
FILED AS OF DATE: 20191108
DATE AS OF CHANGE: 20191108
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Astley-Sparke Philip
CENTRAL INDEX KEY: 0001376491
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38596
FILM NUMBER: 191205494
MAIL ADDRESS:
STREET 1: C/O BIOVEX GROUP, INC.
STREET 2: 34 COMMERCE WAY
CITY: WOBURN
STATE: MA
ZIP: 10801
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Replimune Group, Inc.
CENTRAL INDEX KEY: 0001737953
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 822082553
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 500 UNICORN PARK
CITY: WOBURN
STATE: MA
ZIP: 01801
BUSINESS PHONE: (781) 222-9600
MAIL ADDRESS:
STREET 1: 500 UNICORN PARK
CITY: WOBURN
STATE: MA
ZIP: 01801
4
1
a4.xml
4
X0306
4
2019-11-06
0
0001737953
Replimune Group, Inc.
REPL
0001376491
Astley-Sparke Philip
C/O REPLIMUNE GROUP, INC.
500 UNICORN PARK
WOBURN
MA
01801
1
1
0
0
Executive Chairman
Common Stock
2019-11-06
4
S
0
14500
17.02
D
1369797
D
Common Stock
2019-11-06
4
S
0
14500
17.00
D
1355297
D
The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 7, 2019 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.
Following the sales reported on this Form 4, the reporting person continues to beneficially own 1,355,297 shares of the Issuer's common stock. The reporting person also holds options to acquire 382,571 shares of the Issuer's common stock, 94,103 of which are exercisable as of the date hereof.
/s/ Robert Coffin, attorney-in-fact
2019-11-08